Eli Lilly: promising results in alopecia areata

(CercleFinance.com) - Eli Lilly reported this weekend that patients aged 12 to 18 with severe alopecia areata (AA) experienced 'clinically significant' improvements in hair regrowth on scalp, eyebrows and eyelashes at week 36 after daily treatment with oral baricitinib 4 mg and 2 mg.


Specifically, at week 36, 60% of patients receiving baricitinib 4 mg and 36.9% of patients receiving baricitinib 2 mg saw at least a 50% improvement in their disease, compared with 5.7% on placebo.

What's more, 42.4% of patients receiving baricitinib 4 mg and 27.4% of patients receiving baricitinib 2 mg achieved hair coverage of 80% or more, compared with 4.5% on placebo.

These results from a phase III study were presented at the annual meeting of the American Academy of Dermatology (AAD), which began on March 7 in Orlando, Florida - and ends on March 11.

As a reminder, AA is an immune system disease that causes patchy hair loss on the scalp, face and sometimes other areas of the body, which can progress over time.

We look forward to sharing the results of the longer-term data at upcoming congresses and discussing the findings with global regulators in the coming months," commented Anabela Cardoso, Senior Vice President of Medical Affairs at Lilly Immunology.


Copyright (c) 2025 CercleFinance.com. All rights reserved.